Cantuzumab is a monoclonal antibody specifically targeting MUC1, a mucin frequently overexpressed in various malignancies , including breast cancer. Its mechanism of action involves attaching to MUC1, triggering an antibody-dependent cytotoxic response that causes malignant cell death. Investigations have investigated this agent’s potential in tr